RSS   Newsletter   Contact   Advertise with us

Eli Lilly starts phase 3 trial of antibody treatments against coronavirus in care facilities

Christian Fernsby ▼ | August 5, 2020
Eli Lilly and Company announced the start of its phase 3 trial to study whether one of its experimental coronavirus antibody treatments can prevent the virus infection in residents and staff at U.S. long term care facilities.
Eli Lilly
Phase 3   It will evaluate the efficacy and safety of LY-CoV555
LY-CoV555, the lead antibody from Lilly's collaboration with Canadian biotech AbCellera, is a neutralizing antibody against SARS-CoV-2, the virus that causes COVID-19.

Topics: Eli Lilly

More than 40 percent of coronavirus deaths in the United States linked to long-term care facilities, which creates the urgent need for therapies to prevent COVID-19 in this vulnerable population, Eli Lilly and Company said in a release.

The first-of-its-kind study is expected to enroll up to 2,300 participants who live or work at facilities that have had a recently diagnosed case of COVID-19 and who are now at a high risk of exposure.

It will evaluate the efficacy and safety of LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19, testing whether a single dose of LY-CoV555 reduces the rate of SARS-CoV-2 infection through 4 weeks, as well as complications of COVID-19 through 8 weeks, said the company.

LY-CoV555 is a potent, neutralizing IgG1 monoclonal antibody (mAb) directed against the spike protein of SARS-CoV-2. It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19.